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1. Introduction 
The Electron-Beam Plasma (EBP) is generated by injecting an electron beam (EB) into a 
gaseous medium. The EBP composition is complex: generally it contains molecules, atoms, 
radicals and ions in stable and excited states, plasma electrons and injected beam electrons 
as well. At moderate pressures (Pm <10 kPa) the EBP is strongly nonequilibrium. It means 
that the function of the electron energy distribution in the EBP is non-Maxwellian and heavy 
plasma particles mentioned above are produced in super-equilibrium concentrations, i. e. 
very high densities of ionized and excited particles can be reached. As a result, the EBP 
appears to be chemically active even at low temperature. With respect to non-equilibrium 
plasmas generated in conventional ways (for instance, the plasma of gas discharges) the EBP 
has the following advantages: 
 the EB can be injected into any gases, vapors and gas-vapor mixtures;  
 the EBP bulk does not contract even at very high gas pressures (Pm ~10 kPa and higher); 
 the solid powders and liquid droplets injected into the gas do not prevent the EBP 
generation; large-size bodies can be inserted into the plasma bulk; 
 both solid powders and thing films can be treated in the EBP; 
 very high concentrations of chemically active particles can be obtained even at low (up 
to room) temperatures; 
 the process of the EBP-treatment is absolutely controllable and the treatment results are 
replicable. 
Due to its properties the EBP seems to be very promising for biomaterial treatment and 
especially for the modification of biopolymers.  
The main objective of the study is to experimentally prove the applicability and advantages 
of the electron-beam plasma for actual biological, pharmacological, and medical problems. 
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The production of substances with novel biological and pharmacological properties on the 
base of EBP-modified proteins and polysaccharides is considered as example. 
The products of the fibrinogen proteolytic degradation are known to inhibit the platelet 
aggregation [1]. Being the product of the intermediate stage of the fibrinogen-fibrin polymer 
conversion, fibrin-monomer strongly affects the platelet activity due to two very active sites 
in its molecule. These sites are formed by the proteolytic cleavage in sequence the N-temini 
of the fibrinogen Aα and Bβ chains and release of the fibrinopeptides A and B [2]. Low 
molecular weight products of the fibrin-monomer proteolytic degradation are considered to be 
promising compounds for the platelets inhibition. Unfortunately the industrial fibrin-
monomer can not be degradated by proteolytic enzymes (such as trypsin, plasmin, thrombin, 
and etc.) due to its high polymerization tendency. Therefore, the alternative techniques for 
controllable modification of the fibrin-monomer structure should be found to produce 
peptides with the high antiaggregating activity and without polymerization tendency. 
The natural renewable biopolymers chitin and, especially, chitosan are very promising for 
technological and industrial applications such as agriculture, food processing, cosmetics 
production and others [3, 4]. Chitosan, linear heterocopolymers of β-1,4-linked 2-amino-2-
deoxy-D-glucopyranose and 2-acet-amido-2-deoxy-D-glucopyranose units, has many 
unique biological properties namely high biocompatibility with living tissues, 
biodegrability, ability to the complexation, and low toxicity. In medicine and pharmaceutics 
the water-soluble low molecular weight chitosans (less than 10 kDa) are usually required.  
These substances can be used as immune response-modulating or antibacterial agents, 
sorbents, radioprotectors, and for the production of microcapsules, thing films, and 
substrates for cell cultures [3, 4]. To produce the low molecular weight chitosans (LMWC) 
several techniques, including chemical, enzymatic, and radical treatment have been 
suggested [5]. Simple and rather low-cost chemical treatment is a conventional method, 
however toxic wastes and environment contamination are inherent in the chemical chitin 
and chitosan processing as well as in all techniques mentioned above. Besides, the chemical 
treatment is very time consuming and usually takes several hours. Thus, the development of 
the effective techniques for quick and environment friendly chitosan degradation is the 
burning issue of the day. 
The aims of the present study were as follows: 
1. to experimentally prove the possibility of the EBP-stimulated hydrolysis of proteins and 
polysaccharides as a result of the chitosans plasmachemical processing; 
2. to prove the controlablity of the EBP-treament and to develop the methods for the EBP-
treament control;  
3. to obtain the high yield of the low molecular weight products by optimizing the 
treatment conditions; 
4. to characterize both the structure products of the plasmachemical treatment and their 
bioactivity; 
5. to obtain low molecular products of fibrin-monomer and chitosan with antiaggregating 
and antimicrobial activity, respectively. 
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2. The Electron-Beam Plasmachemical reactor and the treatment 
procedure 
For the controllable biopolymers modification and low molecular mass substances 
production the special Electron Beam Plasmachemical Reactor (EBPR) was designed.  
Figure 1 illustrates the design and operation of the EBPR. The focused continuous EB 3 
generated by the electron-beam gun 1 which is located in the high vacuum chamber 2 is 
injected into the working chamber 5 filled with the plasma-generating gas through the 
specially designed double-stage gas-dynamic injection window 4 [6]. Oxygen, nitrogen, 
noble gases, gaseous hydrocarbons and other atomic and molecular gases, water vapor, and 
vapors of some organic substances can be used for the EBP generation. The electrically 
heated evaporator 11 is placed inside the reaction chamber, as shown in figure 1, to add the 
vapor to the plasma-generating gas. Evidently, the pure vapor can be used for the EBP 
generation and, in this case, the reaction chamber is kept at given constant pressure by 
adjusting the heater power. 
In passing through the gas the EB is scattered in elastic collisions and the energy of fast 
electrons gradually diminishes during various inelastic interactions with the medium 
(ionization, excitation, dissociation).  As a result, the cloud 10 of the EBP is generated, all 
plasma parameters being functions of x, y, and z coordinates (z is the axis of the EB 
injection). 
 
1 – electron beam; 2 – high vacuum chamber; 3 – EB; 4 – injection window; 5 – working chamber; 6 – mixing layer of 
the powder to be treated; 7 – piezoceramic plate; 8 – temperature sensor; 9 – glass container; 10 – EBP cloud;  11 – 
water evaporator; 12 – scanning system. 
Figure 1. The design of the plasmachemical reactor and the treatment procedure  
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The electromagnetic scanning system 12, which is placed inside the working chamber near 
the injection window is able to deflect the injected EB axis in x and y directions and, 
therefore, to control the spatial distribution of the plasma particles over the plasma bulk. 
The working chamber is preliminary evacuated to pressure 10-2 Torr and then filled with 
plasma generating media. The samples to be treated were inserted into the EBPR reaction 
zone as solid powders with characteristic particle size ~ 100 mcm and as thing films. The 
powder of the substance to be treated partially fills the glass container 9. Thin plate 7 made 
of piezoelectric ceramics is placed on the container bottom. Being fed with AC-voltage the 
plate vibrates, throws up the powder particles and forms the mixing layer 6 of the treated 
material. The miniature thermo-sensor 8 is inserted into the container to monitor the material 
temperature Ts during the treatment. To prevent the thermal distraction of the biological 
material all samples were processed at Ts<50 C. In the case of proteins Ts was ~ 37 C. The 
temperature control was carried out by selecting the EB current Ib (1 < Ib < 100 mA). 
Special software was developed to calculate irradiation doses as functions of the electron 
beam characteristics, gas pressure and chemical composition, treatment duration, and beam 
scanning parameters [7], see section “The control of EBP-modification process”. 
3. The operation modes of the EBPR 
The reaction zone (item 6 in figure 1) of the EBPR is the plasma of an aerosol, as it is 
sometimes called “dusty plasma”. In general, the operation parameters of the reactor 
responsible for the properties of the plasma of this kind are as follows. 
1. The beam parameters: the initial electron energy (Eb), that is equal to the accelerating 
voltage of the electron gun, and the EB power (N) injected into the reaction chamber. 
2. The power N is less than the original power of the EB (Nb = EbIb, where Ib is the current 
of the beam generated by the gun) since the EB is partially absorbed by the injection 
window. The transparency coefficient of the injection window was specially measured 
under various conditions of the plasma generation and the data of the measurements 
were used to characterize the parameters of the material treatment. The values of both 
Eb and Ib are measured inside the high voltage power source, supplying the gun, and 
are displayed on the control panel of the EBP generator. 
3. The plasma-generating gas parameters: the pressure (Pm) and temperature (Tm) of the 
gas; its chemical composition. 
4. The parameters of the dust: dimensions and shape of the dust particles; the dust 
density, i.e. the number of the dust particles per unit volume (nd); physical properties of 
the dust material (chemical composition, density, coefficients of the electron emission 
and some others); 
5. The geometry of the plasma bulk, especially the distance (z0) between the injection 
window outlet and mixing layer. 
In comparison with the plasma treatment of conventional powder materials (e.g. metals, 
ceramics, carbon, etc.) the biomaterials processing has at least three important peculiarities.  
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1. The biomaterials should be processed at low temperatures (Ts <50 C) to prevent the 
material destruction caused by overheating. 
2. The effect of the biomaterials modification was found to crucially depend on the dose of 
the biomaterial irradiation by the EBP particles. Usually, the material properties, 
especially its bioactivity, change abruptly when the certain irradiation dose has been 
accumulated, but if the dose exceeds this threshold level the bioactivity doesn’t increase 
any more [8]. 
3. The direct bombardment by high energy electrons (Eb 100 keV and higher) is known to 
damage or destruct bio-molecules [9, 10]. 
It means that biomaterials should be processed by the EBP generated by the beams of the 
moderate Eb and that the plasma particles densities and the local power input must be 
uniform over the reaction bulk, predictable and controllable.  
The controlling system of the EBPR is able to vary Eb (25 < Eb < 40 keV) and Ib (1 < Ib < 100 
mA). The system supports various scanning modes of the EB injected into the reaction 
chamber (linear in x or y directions, circle or ellipse, rectangular raster, multi-triangle or 
saw-tooth), and both the amplitudes and frequencies of the scanning can be varied. The 
controlling system also supports the intermittent modes of the EB generation that enables to 
the biomaterials treatment in the decaying EBP. The pulse frequency can be tuned within 
the range 1-1000 Hz; the shortest and longest pauses between the EB pulses are 10-3 s and 1.0 
s respectively. 
The EBPR controlling system also includes the gas-feeding unit which has a feedback with 
the valves of the vacuum system. The gas-feeding system supplies one or two plasma-
generating gases to the reaction chamber from separate external vessels, thereby keeping the 
total pressure of the gas mixture (within the range 0,1 < Pm < 100 Torr) and partial pressures 
of the mixture components constant. 
4. The tests of the EBPR and optimization of the biomaterial treatment 
procedure 
The computer simulation of the dusty EBP was carried out to preliminary estimate optimal 
parameters of the biomaterial treatment. The following processes were taken into account: 
- The scattering of high-energy electrons by the gas molecules and dust particles; 
- The gas ionization by high-energy electrons; 
- The capture of high-energy electrons by dust particles; 
- The gas and dust heating; 
- The heat transfer between the gas and dust particles; 
- The plasmachemical reactions in the gas; 
- The electron-ion recombination on the dust surface; 
- The electric charging of the dust. 
The local EB power input Q(x,y,z), densities of charged particles of the EBP in various zones 
of the plasma bulk (including the mixing layer), and the temperature of the dust particles 
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(Ts) were calculated for various modes of the EB scanning modes and various distances z0. 
The results of the computer simulations were verified experimentally for some modeling 
plasma-generating gases at pressures 1,0 < Pm < 50 Torr and dust materials (103 < nd < 106 cm-
3). The diagnostic complex containing optical, microwave, calorimetric and some other 
devices was developed to measure values of Q(x,y,z), Ts, and densities of the plasma 
particles. 
Figure 2 illustrates the obtained experimental data in comparison with the calculations. It 
presents the radial distributions of the local power input (curves 1-3) and steady-state 
temperature of the dust particles (curves 4, 5) in the air-EBP at pressure Pm = 4 Torr; z0 = 200 
mm. All quantities plotted along the axis of ordinates are normalized by their values at the 
point x = 0, y = 0, i.e. at the center of the given cross-section z0 of the plasma cloud. 
The best combinations of the EBPR operating parameters were found for various plasma-
generating gases (1,0 < Pm < 50 Torr) and dust densities. For the experiments described they 
were: plasma generating gases – water vapor, oxygen, and helium, Eb = 30 keV, Ib = 2-5 mA, 
Pm = 9 Torr  (water vapor), 4 Torr (oxygen) and 40 Torr (helium). The axis of the injected EB 
was scanned in x- and y-directions to form the square raster 13x13 cm2 in the plane of the 
mixing layer. Both continuous and intermittent modes of the EBP generation were applied. 
The container with the powder to be treated was located at the distance z0= 25 cm from the 
injection window. 
 
Figure 2. Radial distributions of the local power input (curves 1-3) and steady-state temperature of the 
dust particles (curves 4, 5): 1 – simulations, 2 – calorimetric measurements, 3 – optical measurements, 4 
– thermo-sensor measurements in the non-scanning plasma cloud, 5 –  thermo-sensor measurements in 
the plasma generated by the EB scanning along the x-axis. 
Both the experiments and simulation showed that the powder is uniformly heated to the 
temperature Ts <50 C and the concentrations of the chemically active plasma particles can 
reach 109-1011 cm-3 in the vicinity of the material to be treated. The concentrations of the 
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charged plasma particles (secondary electrons and ions) were measured by means of an 
open barrel-shaped microwave cavity [11] and data of the computer simulation can be used 
to estimate the concentrations of the neutral ones (molecules, atoms, radicals) [6]. The 
appropriate duration of the treatment procedure was experimentally found to achieve the 
required dose of the material irradiation. 
5. The control of EBP-modification process 
In general the following parameters are responsible for the processes (and eventually for the 
results) of the materials modification: 
- The parameters of the EB being injected: electron energy Eb, integral current of the beam 
Ib and current density jb. For the EBPR under consideration these parameters are 
completely predetermined by the reactor design: the designs of the electron gun and 
injection window, the gun accelerating voltage U. 
- The medium properties: chemical composition, pressure Pm and temperature Tm of the 
gas. 
- The geometry of the reaction bulk: location of the reaction zone inside the EBP cloud, 
amplitude and frequency of the EB scanning. 
- Characteristic size of the powder particles and density of the aerosol in the reaction 
volume. 
- The total dozes of the powder particle irradiation by plasma particles of various kinds; 
the dozes being, obviously, determined by the fluxes of these particles on the powder 
surface and by the treatment duration. 
Special software was developed to simulate the processes of the EBP generation and 
plasma-powder interaction, predict the effect of the modification under various 
experimental conditions, and optimize the treatment procedure. The description of the 
numerical algorithms and physical and plasmachemical models used for the software is 
beyond the paper involved. Here we demonstrate only the application of the software. 
Figure 3 presents the incident fluxes of the plasma particles on one cm2 of the container 
bottom (item 9 in Figure 1) calculated as a function of x- and y-distances from the container 
center. The EB axis scans in x- and y-directions, the amplitudes of scanning being equal to 
±13 cm. Figure 3(a) illustrates the bio-material treatment in helium at pressure 40 Torr and 
Figure 3(b) - in water vapor at pressure 10 Torr. In the first case, four rigid peaks of the 
incident power appear at the raster corners and a sufficiently flat valley ≈5×5 cm−2 occurs 
between the peaks. The intensity of irradiation in the valley is about half of that on the 
peaks. In the EBP of water vapor a flat plateau ≈7×7 cm−2 with a uniform flux of plasma 
particles is formed. In real experiments the container with the material to be treated was 
placed in the zones of uniform incident fluxes. 
If the container location and scanning parameters are known the values of plasma 
particles fluxes can be found in terms of local concentrations n (cm-3) of these particles 
inside the container. The functions n = n(Pm, Ib, U) were calculated for every plasma-
generating gas used in our experiments. The variations n = n(Pm) of the ion concentration 
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in the EBP of argon excited by the EB at two different values of the beam current Ib = 15 
and Ib =7,5 mA (curves 1 and 2 respectively) are presented in Figure 4 as the example of 
numerical simulations. In this figure all concentration values n are divided by the 
maximum value of the particles concentration nmax for Ib = 15 mA. The Figure 3 shows that 
there are optimal values of Pm for given Ib and U, these optimal values being individual 
for each gas.  
 
Figure 3. a.The incident radiation power of fast electrons on 1 cm2 of the sample surface calculated as a 
function of x- and y-distances from the sample center: the treatment in the helium EBP at pressure 40 
Torr. b.The incident radiation power of fast electrons on 1 cm2 of the sample surface calculated as a 
function of x- and y-distances. 
If optimal values of Pm are found the total dose of the powder particles irradiation can be 
calculated. In particular, the treatment durations  required to irradiate the powder by equal 
dozes at variable gas pressures were calculated and relevant experiments in various gases 
were planned and carried out. Experiments of this kind showed the modification effect in 
the organic materials under consideration to appear when the accumulated doze exceeded 
some threshold value. 
The material temperature can be controlled by varying the gas pressure value during the 
treatment. The lower the gas pressure - the higher the sample temperature since the 
scattering and absorption of the EB in gaseous media are more intensive at higher pressures 
than at lower ones. If higher sample temperature is required to obtain the desirable 
modification effect the gas pressure should be reduced. For this reason the polysaccharides 
were treated at lower pressures than the proteins because the higher temperature (about 400 
K) was optimal for effective polysaccharides modification. On the contrary, when the 
proteins were treated in helium the higher pressures (Pm 40 Torr) were required to prevent 
the sample from overheating. It was because of the restrictions on the material temperature 
that the working pressures in the reaction chamber of the EBPR sometimes differed from 
their optimal values found as the maximum of the functions n = n(Pm,  Ib). 
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Figure 4. Concentrations of excited particles in the EBP of argon filling the reaction chamber as a 
function of the gas pressure, U = 25 kV, z = 130 mm: Ib = 15 mA (curve 1), Ib = 7,5 mA (curve 2). 
6. Original substances and methods used to investigate products of their 
EBP-modification 
The plasmachemical modification of the following natural materials was studied in detail: 
- synthetic derivative of 2-aminopropanoic acid (alanine) - natural alpha-amino acid with 
artificially inserted pyrozolidine cycles; 
- bovine serum albumin (BSA, Mr = 66 kDa) 
- fibrin-monomer (FM, Mr 340 kDa) - the natural protein which is contained in the blood 
of mammalians. 
- cellulose materials (pure cellulose, wooden sawdust, and crushed paper); 
- chitosan from crab or shrimp shells with the degree of deacetylation and molecular 
weight of 95% and 500 kDa, respectively; 
- peat of some peat deposits in Russia. 
The original powders of polysaccharides were additionally ground in the laboratory mill 
before treatment. Average final sizes of the powder particles were within the range 10-40 
m. The proteins were treated both in forms of solid powders (BSA and FM) and thing films 
(BSA). To form a film BSA was dissolved in distilled water and than water evaporation 
under vacuum was performed. The thickness of the formed film was 1 μm.  
The following properties of EBP-modified products were of particular interest: 
- water solubility of the materials after plasma treatment; 
- molecular mass; 
- spectral characteristics in IR- and UV-regions; 
n / nmax 
0,25
0,5 
0,75
2
1
1,0
Pm , kPa
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- electrophoretic mobility; 
- specific antigenic properties; 
- biological activities. 
Solubility measurements. 100±0,1 mg of the preliminary dried sample (ms) were placed into a 
tube and 1,5 ml of distilled water were added to the sample. The resulting mixture was 
incubated for 24 h at room temperature under periodic mixing. After the incubation the 
mixture was centrifuged for 5 min and 1 ml of centrifugate was taken and dried. The mass 
of the dry residue (mdr) was measured with an accuracy ±0,1 mg. The sample solubility was 
calculated as the (mdr/ ms)100% ratio. 
Molecular mass characterization. To characterize the molecular masses of the EBP-treatment 
products the exclusion chromatography was applied. The chromatograph Staier (Russia) 
and the chromatographic column Phenomenex BioSep-Sec-S-3000 (USA) with the efficiency of 
30000 theoretical plates were used. The analysis conditions were as follows: the elutriating 
agent – 0,1 M phosphate buffer (pH 6,86) containing 0,05% NaN3; the elution rate - 1 ml/min; 
temperature - 30оС; UV-detector with the wavelength 280 nm. 
The effects of the EBP-treatment on proteins molecular mass and structure were detected 
also by means of the UV- and IR-spectroscopy, ion-exchange chromatography, 
immunoelectrophoresis and PAGE-electrophoresis as well [12]. 
UV-spectroscopy. The measurements were performed with the spectrometer Shimadzu UV-
3600 (Japan). The IR-spectra were registered within wavelength λ = 226-418 nm. 
IR-spectroscopy. The measurements were performed with the IR-spectrometer Portmann 
Instruments AG (Switzerland) equipped with the ZnSe crystal. The IR-spectra were 
registered within wave numbers ν = 500-3600 cm-1. To improve the spectral resolution 
Fourier analysis was performed. 
Ion-exachange chromatography. The ion-exchange chromatography (with the preliminary acid 
hydrolysis of the protein) was performed to reveal the changes in the amino acid 
composition of proteins due to the EBP-modification. The analyzer AAA-339 M (Hungary) 
was used. To quantitatively analyze the sulfur-containing amino acids (cystine and 
methionine) the biomaterial was treated with the performic acid before the hydrolysis 
procedure. Totally 17 basic amino acids contents were measured. The accuracy of the 
mesuarment was 10%. 
Immunoelectrophoresis. The electrophoresis was performed in the 1,4% agar gel [13]. The 
commercial specific antiserum to human fibrinogen was used to characterize and compare 
antigenic structure of the FM before and after plasmachemical treatment. 
PAGE-electrophoresis was performed according to Laemmli U.K. [14].  
Biological activity of the EBP-produced low molecular weight chitosans (LMCW). The inhibition of 
the bacteria growth in vitro was measured to quantitatively characterize the bioactivity of 
LMCW obtained by the plasma treatment, gram-positive (S. aureus), gram-negative (E. coli, 
Ps. aeruginosa) microorganisms and yeast-like fungi (C. albicans) being used in these 
experiments. 
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Biological activity of the EBP-treated alanine derivative and fibrin-monomer. The EBP-modification 
products of fibrin-monomer were tested as the platelet aggregation inhibitors [15]. The platelet 
aggregation A (%) was measured by the turbodimetric method [16] and A was defined as the 
ratio of the light transparency of the platelet suspension after ceasing the aggregation process 
to the initial value of the light transparency. The aggregation was monitored by the 
aggregometer Chronolog Corporation (USA), adenosine diphosphoric acid (ADP, final 
concentration 110-5 M; Boechringer Mannheim, Germany) being used as an aggregation agent. 
7. The amino-acids treatment in the Electron-Beam Plasma 
Some natural amino acids with artificially inserted pirozolidine cycles into their structures 
were used as original substances and the products of their modification in the EBP of helium 
and water vapor were tested as inhibitors of the human platelet aggregation. Preliminary 
analysis showed the substances of this class to be promising as active agents for medical 
therapy of acute coronary events, and cardiovascular diseases that remain the leading cause 
of mortality. Their advantages are due to selectivity of the pharmacology action and limited 
side effects. 
The powder samples (≈ 50 mg in mass) of the original derivative of alanine were treated in 
the EBP of water vapor at pressure Pm ≈ 9 Torr for variable time duration τ = 45-300 s. The 
typical EB power was Nb ≈ 0,1 kW, the sample temperature Ts under the treatment could be 
varied within the range 30-110 °C. 
The untreated compound was not dissolvable in distilled water at room temperature and the 
water heating up to 90 °C followed by cooling to 25 °C was required to carry out the control 
experiments and to study its effect on human platelet aggregation in vitro. The treated 
substance became partially water-soluble at room temperature and the solution at maximum 
concentration was added to the platelet suspension to measure the aggregation degree. 
The untreated derivative decreased human platelet aggregation only to 46±2% with respect 
to control (56±2%). The water-soluble products of plasma treatment reduced the aggregation 
degree up to ≈ 30 %, i.e. being treated by the EBP for 5 min the studied substance reduced 
the platelet aggregation activity by approximately 45 % (Table 1). 
 
ADP 
ADP + 
untreated 
amino acid 
ADP + treated amino acid 
 = 45 s, 
Ts = 38 C 
 = 90 s, 
Ts = 38 C 
 = 180 s, 
Ts = 38 C 
 = 180 s, 
Ts = 55 C 
 = 300 s, 
Ts = 55 C 
562% 462% 413% 413% 343% 323% 313% 
Table 1. The effect of the plasma modification in the EBP of water vapor on the anti-aggregation 
activity of the tested alanine derivative (in vitro):  the aggregation degree as a function of the treatment 
duration  and temperature of the substance Ts under the treatment procedure 
The effect of the treatment duration on their anti-aggregation activity increased as the 
treatment prolonged, the anti-aggregation activity rising sharply at 90 < τ < 180 s. At shorter 
durations τ < τ0 the plasma did not modify the original substance and the longer treatment τ 
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> τ0 resulted in insignificant additional effect. Moderate sample heating amplified the 
treatment effect slightly, i.e. plasmachemical processes are responsible for the modification. 
8. The proteins treatment in the Electron-Beam Plasma 
Originally water-indissoluble native FM was found to become soluble at room temperature 
without bunching. Figure 5 presents the UV-spectra of absorption for original and treated 
fibrin-monomer. The spectral curves of the modified products differ radically from the 
curve representing the original substance. This supports the hypothesis of the changes in the 
physical-chemical properties due to the plasmachemical treatment in the EBP. 
 
Figure 5. UV-spectra of the light absorption of fibrin-monomer solutions 
Radical changes in the FM structure after the EBP-treatment were detected by means of 
immunoelectrophoresis. The EBP-modified products did not exhibit the specific antigenic 
properties of original FM and did not react with specific antibodies, while the native 
substance gave specific precipitation line (Figure 6). 
To reveal the changes in the primary and secondary structure of the EBP-treated FM the IR-
spectroscopy was used. The IR-spectra analysis showed (Figure 7 a, b): 
1. The maximum of the absorbance in the band complex ν = 1711-1714 cm-1 (complex of 
amide II bands) displaced from 1711 cm-1 (native FM) to 1712 cm-1 and 1712 cm-1 (FM 
treated in the EBP of helium and water vapor, respectively). This indicates the partial 
destruction of peptide –CO-NH-bonds in the primary FM structure. 
2. The spectral bands ν = 3354 cm-1 and ν = 3475 cm-1 characterize the valence oscillations 
of –N-H-bonds. The expansion of this band in the spectra of the EBP-modified FM 
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confirms the partial destruction of the native protein molecule and low molecular 
weight peptides formation. 
3. The spectral bands ν = 1163 cm-1 and ν = 1471 cm-1 which characterize the oxidation of 
disulfide bounds are most intensive in the IR-spectra of EPB-treated FM.  
These facts confirm that the EBR-treatment of the FM for  = 5 min has caused the partial 
destruction of the peptide –CO-NH-bonds in the primary FM structure and the oxidation of 
the disulfide bonds responsible for the tertiary peptides structure. 
All changes were more significant in the case of the water vapor EBP, which could result 
from the higher chemical activity of the water plasmolysis products (e.g. OH). 
 
Figure 6. The immunoelectrophoresis of FM before and after the EBP-treatment 
The plasma treatment reduced the amount of amino acids forming the primary protein 
structure (the content of 17 amino acids was studied). The percentages of lysine, threonine, 
glutamic acid, cystine, tyrosine and phenylalanine were found to be reduced significantly 
(down to 2 times with respect to the native FM, Table 2). The reduction of aspartic acid, 
serine, glycine, valine, methionine, leucine and isoleucine was not so sharp (only 1,3-1,5 
times with respect to the native FM). The intensive peak of free NH3 was detected in the 
chromatogram of the modified products whereas it was not found in the chromatogram of 
the original peptide.  
To characterize the molecular masses of the EBP-treatment products the exclusion 
chromatography was applied. The peaks corresponding to 6 individual peptides with the 
elution times 12,30; 12,55; 13,17; 13,70; and 13,94 min were observed in the exclusion 
chromatograms of the FM modified by the EBP (Figure 8). 
The water-soluble products of the FM appropriately treated by the EBP of both helium and 
water vapor were found to decrease the platelet aggregation down to 33-35 % in vitro at 
final concentrations 1×10-5-1 mg/ml, treatment in the water vapor EBP being more effective 
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than that in helium (Figure 9). The effect of the treatment on the FM anti-aggregation 
activity increased sharply with the time within the range 90 <  < 180 s. The longer treatment 
resulted in a negligible additional effect. The peak corresponding to the elution time 12,3 
min (molecular weight  650 Da) was observed at the exclusion chromatograms of the FM 
modified in the EBP of helium and EBP of water vapor at a moderate irradiation dose 
whereas the FM treated EBP of water vapor at lower or higher irradiation doses did not 
produce the peak (Figure 8). This peptide is likely to be responsible for the inhibiting of the 
platelet aggregation. 
 
Figure 7. a. IR-spectra of the native and EBP-treated fibrin-monomer (τ = 5 min): native FM – blue line, 
FM treated in the EBP of helium – red line, FM treated in the EBP of water vapor – green line; b.IR-
spectra of the native and EBP-treated fibrin-monomer (τ = 5 min): native FM – red line, FM treated in 
the EBP of helium – blue line, FM treated in the EBP of water vapor – green line 
 
Bio-Medical Applications of the Electron-Beam Plasma 299 
Amino acid Amino acid content, % 
Native FM FM, treated in water 
vapor EPB 
FM, treated in helium 
EPB 
Lysine 0,26 0,13 0,13 
Threonine 0,24 0,15 0,18 
Glutamic acid 0,53 0,36 0,40 
Cystine 0,068 0,039 0,051 
Tyrosine 0,1 0,09 0,09 
Phenylalanine 0,16 0,09 0,10 
Aspartic acid 0,64 0,49 0,53 
Serine 0,29 0,22 0,21 
Glycine 0,24 0,22 0,22 
Valine 0,15 0,12 0,13 
Methionine 0,15 0,11 0,12 
Leucine 0,24 0,17 0,19 
Isoleucine 0,14 0,10 0,12 
Table 2. The amino acid content of FM before and after EBP-treatment 
 
 
 
Figure 8. The chromatograms of the FM treated in the EBP of helium (curve 1), water vapor at 
moderate irradiation dose ( curve 2) and at low irradiation dose (curve 3)   
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Figure 9. The reduction of the ADP-induced platelet aggregation by products of the FM modification in 
the EBP of water vapor and helium 
The powder of globular protein BSA was treated in the EBP as well. The solubility of the 
native BSA was 100%. Contrary to the EPB-treated FM the products of the EBP-modification 
became partially indissoluble in distilled water and the solubility decrease could be 
observed by the unaided eye. The water solution of the treated BSA contained the of 
undissolved protein particles, the solution of native BSA was absolutely clear. The latter 
indicates that the BSA polymerization has occurred due to the EBP-treatment.   
No differences in either BSA structure were found in the IR-spectrograms, PAGEs (Figure 
10), changes in its amino acid composition were not observed also. Since the molecular mass 
of the BSA is significantly less than that of the fibrin-monomer the BSA may be more 
resistant to the EBP treatment and no changes in the amino acids content and their structure 
in the EBP-modified BSA occur. On the other hand, minor quantities of the low molecular 
products which could be formed due to the EBP-treatment of the BSA are undetectable by 
the relatively low-sensitive PAGE technique. 
The exclusion chromatography, that has higher sensitivity, was used to detect the products 
of the BSA treatment. The peaks corresponding to the individual peptides with molecular 
weights >800 kDa, 350 kDa, 150 kDa, 66 kDa and less (elution times 5,6; 7,2; 8,0; 8,7 min and 
more than 8,7 min, respectively) were observed in the exclusion chromatograms of the BSA 
modified by the EBP of both oxygen and water vapor (Figure 11).The treatment of the BSA 
for longer time (up to 20 min) did not result in the additional changes of its properties and 
composition.  
 
Bio-Medical Applications of the Electron-Beam Plasma 301 
Whereas the products of the EBP-induced polymerization and very small concentration of 
low molecular peptides are detected the most significant peak (>2400 mV) corresponds to 
protein with molecular mass 66 kDa i.e. to the unmodified BSA. This confirms that though 
the EBP-treatment of the BSA causes some changes in its structure they are not as 
pronounced as in the case of the fibrin-monomer treatment. Therefore the modification 
effect of the plasma treatment depends on the size and structure of the original protein 
molecule. 
 
Figure 10. PAGE-electrophoresis of four BSA samples: 1 – control BSA; 2, 3 and 4 – BSA treated in the 
EBP of water vapor for 2,5, 5 and 10 min, respectively 
 
Figure 11. The exclusion chromatogram of BSA powder treated in EBP of oxygen (τ = 10 min) 
On the other hand the small concentration of low molecular weight peptides is probably due 
to a small depth (a few micrometers) of a powder particle involved in the plasmachemical 
treatment. To enhance the homogeneity of the EBP-modification, the samples of globular 
protein were treated in the form of thin films. Such treatment arrangement can considerably 
1 2 3 4
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increase the yield of low molecular weight products with the comparison to the powdered 
samples. 
The PAGE of the BSA samples modified as films in EBP revealed a dramatic decrease in the 
intensity of the albumin band and the formation of a number of low molecular peptides, of 
which most have a molecular mass below 14 kDa. The exclusion chromatograms also 
displayed numerous peaks corresponding to low molecular mass products with elution 
times of 11,8; 15,1; and 17 min (Figure 12). The concentration of the low molecular mass 
compounds depended on the plasma treatment time and the nature of the plasma gas: as the 
treatment time increased, their concentration grew, and BSA degradation being more 
significant in the water vapor EBP. A decrease in the content of almost all amino acids was 
observed. The most significant decrease (by 2–3,5 times with respect to untreated BSA) was 
in the case of lysine, aspartic and glutamic acids, tyrosine, and cystine (Table 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. The exclusion chromatogram of BSA thing film treated in EBP of oxygen (τ = 10 min) 
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Amino acid Amino acid content, % 
Native BSA BSA, treated in 
water vapor EPB
τ = 5 min 
BSA, treated in 
oxygen EPB 
τ = 5 min 
BSA, treated in 
oxygen EPB 
τ = 10 min 
Lysine 10,25 3,68 2,73 2,45 
Threonine 5,02 2,65 2,63 2,27 
Glutamic acid 16,78 5,78 6,64 5,90 
Cystine 4,73 1,78 2,07 1,75 
Tyrosine 4,30 1,70 1,55 1,79 
Phenylalanine 5,01 3,43 3,37 2,90 
Aspartic acid 9,17 3,86 5,12 5,14 
Serine 3,75 2,03 2,11 1,89 
Glycine 1,45 2,13 2,48 2,54 
Valine 4,45 3,70 3,25 3,51 
Methionine 2,02 0,76 0,89 0,63 
Leucine 9,61 6,55 6,05 5,47 
Isoleucine 1,85 1,34 3,37 2,90 
Table 3. The amino acid content of BSA before and after EBP-treatment (BSA was treared as thing film) 
9. Discussions and conclusions 
1. Our experiments show that the powders of various proteins can be effectively modified 
in the EBP and that the plasmachemical processes are responsible for the 
modification. With the use of special procedures of sample preparation for the EBP-
treatment, it is possible not only to increase the yield of plasma modification products 
but also to effectively control their composition. It was found that unlike powdered 
samples, the materials in the form of a freeze dried film of ~1 μm thickness can be 
homogeneously treated to an extent sufficient for the practical use of the compounds 
produced.  
2. Plasmachemical reactions in thin films occur throughout the entire volume of the 
sample, leading to the formation of final low molecular mass products. The powdered 
samples are characterized by a thin surface layer (of at most 10 μm in thickness) in 
which the effective modification of the protein takes place. The protein remains intact in 
deep layers of such samples, and polymerization of protein molecules is likely to occur 
in intermediate layers. Our results are consisted with the data obtained in some other 
studies [17, 18]. The destruction of BSA thing films was also observed in the 
experiments using the atmospheric pressure glow discharge. Nevertheless the effective 
BSA degradation in the atmospheric pressure glow discharge was observed when the 
very small amounts of the protein sample (~20 μl) were treated [18]. Thus, the EBP-
treatment seems to be more powerful technique for the protein degradation and low 
molecular peptides formation with respect to the gas-discharge plasmas. 
The following factors influence the biomaterial placed into the plasma cloud: 
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 the fast electrons of the partially degraded EB that bombard the sample;  
 the secondary electrons of moderate energy produced in the EBP can also act on the 
powder; 
 the EBP-radiation, especially UV one and X-ray (bremsstrahlung); 
 chemically active heavy particles of the EBP (excited molecules and atoms, ions, 
radicals). This factor is likely plays the pivotal role for the low molecular peptides 
formation and for the production of bioactive products [19]. Due to the action of the 
reactive oxygen species (ROS) the destruction of the peptide bonds occures. The Figure 
13 illustrates the possible mechanism of peptide bonds cleavage [20]. The formation of 
intermolecular cross-links can also occure under the ROS influence and the production 
of some high molecular weight substances was detected by the exclusion 
chromatography after the EBP-treament of fibrin-monomer powder (see Figure 8). 
Some new chemical groups might be formed in the molecule structure during the 
treatment in the EBP. For instance, the ROS generated in the EBP of the water vapor or 
oxygen can react with the amino acid residues resulting in their oxidation and the 
formation of various keto-products. The formation of such oxidized substances (e.g. 
pyruvic acid, kynurenine, glutamic semialdehyde, disulfides, cysteic acid [21]) is 
possible reason for the changes in the UV-spectra and amino acid composition (see 
Figure 5 and Tables 2 and 3). 
3. the EBPR with the aerosol reaction zone was successfully used to produce compounds 
with new pharmacological activity and therapeutic effect, e.g. for the production of 
effective platelet aggregation antagonists. Also the destruction of peptides in the EBP 
can be used for the effective sterelization of medical instruments, inactivation of 
pathogenic bateria and prion proteins.  
 
Figure 13. The scheme of peptide bound degradation and cross-links formation under ROS action in 
the EBP of the water vapor or oxygen 
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10. The polysaccharides treatment in the Electron-Beam Plasma 
The plasmachemical modifications of cellulose materials, peat, and chitosan in EBP of O2, 
He, and H2O, are studied. The yield (S, %) and the average molecular mass of water-soluble 
products extracted from the solution were taken as the quantitative criteria for the 
modification. Note, typical content of water-soluble substances in untreated cellulose 
materials does not exceed 1–2%.The molecular mass of the cellulose may reach several 
million. The water-soluble products yield depends upon the processing conditions and has a 
maximum value Smax for each plasma-generating gas: for oxygen plasma Smax ≈ 45%, for 
plasma of water vapor Smax ≈ 56%, which is reached during certain time periods of the 
treatment τ0. At first the dependence S(τ) increases smoothly, then - steeply in the vicinity of 
τ0 after which the yield of the water-soluble products does not change whatever the time of 
the treatment could be (Figure 14). The NMR- and IR-spectroscopy analyses showed the 
final water-soluble products of the cellulose modification to be β-(C1→C4)-tetrasaccharide, 
the molecule structure and chemical bonds of the products being identified. In particular, 
low-molecular products (M ≈250–800 Da) have attached carbonyl and/or carboxyl groups on 
their ends if the original materials have been treated in O2 or H2O plasmas. 
 
Figure 14. The modification effect in studied polysaccharides as a function of the treatment duration in 
the EBP of water vapor 
The products of the EBP modification of all the substances mentioned above turned out to 
be bioactive. For instance, modified cellulose and peat are effective substratesfor 
microorganisms and fungi: the yield of the yeastrel on the plasmachemically treated peat 
reached 0,14 kg per 1 kg of the peat, whereas the productivity of the untreated substrate was 
only 0,053 kg. 
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The original chitosan was not water-soluble while its EBP-treament products became 
soluble and the effect increased with the prolongation of τ. The maximum yield of water-
soluble substances was obtained after 10 min and the solubility of these products was up to 
95% up at room temperature.  
The exclusion chromatography of the EBP-treated chitosan revealed the formation of a 
number of LMWC with molecular weight varied from 18 kDa to monomeric fragments 
(Figure 15). The majority of products formed with the EBP-treatment were oligosaccharides 
with the molecular mass 1 kDa (the elution time 11,3 min). 
 
 
Figure 15. The exclusion chromatogram of chitosan treated in the EBP of water vapor (τ = 10 min) 
The degradation of the original polymer is due to the action of free radicals formed in the 
EBP. Active oxygen particles (O, O, singlet oxygen) that are produced in plasmachemical 
processes and the products of the water plasmolisys (e.g. OH) are likely to be of the most 
importance. These chemically active particles break the β-1,4 glycosidic bound and 
decrease the chitosan molecular weight Figure 16 illustrates the possible degradation 
mechanism [22].  
To quantitatively characterize the bioactivity of the EBPproduced LMCW the bacteria 
growth in vitro was studied. The LMCW produced by the EBP-treatment in water vapor at 
concentration 1000 μg/ml were found to completely suppress the multiplication of colon 
bacillus, aurococcus and yeast-like fungi. At lower doses the EBP-treatment products were 
also active and strongly inhibited the microorganism multiplication (Table 4). 
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Test 
microorganism 
EBP-treated chitosan concentration, μg/ml Control 
1000 500 250 125 
E. coli ---- ± ± + + 
Ps. aeruginosa + + + + + 
S. aureus ---- ± + + + 
C. albicans ---- ± + + + 
--- the absence of microorganism growth; ± weak microorganism growth; + microorganism growth comparable with 
reference sample 
Table 4. The microorganism growth under EBP-treated chitosan 
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Figure 16. The scheme of chitosan degradation under hydroxyl radical action in the EBP of the water 
vapor [22] 
11. Discussions and conclusions 
 The possibility of the EBP-stimulated hydrolysis of native polysaccharides and 
formation of water-soluble low molecular weight bioactive products was proved 
experimentally. The yield of the water-soluble products depends on the doze of the 
irradiation by the plasma particles. Other things being equal, the yield of the bioactive 
products began to increase abruptly at particular duration of treatment 0. At shorter 
duration  < 0 the plasma didn’t modify the original substance and the longer treatment 
 > 0 resulted in an insignificant additional effect.   
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 The 95% yield of low molecular weight EBP-treatment products was attained by 
optimizing the treatment procedure. The high yields of low molecular weight water 
soluble products are obtained at treatment time ~10 min whereas the traditional 
chitosan hydrolysis usually takes several days. The hazardous by-products and toxic 
wastes are not generated during the EBP-treatment. 
 The low molecular water-soluble forms of the chitosan obtained by its treatment in the 
EBP of oxygen and water vapor were found to inhibit the multiplication of colon 
bacillus, aurococcus and yeast-like fungi. The LMWC with molecular weight 30-180 
kDa and chitooligosaccharide mixtures are known to possess antimicrobial properties 
[22, 23]. We suppose that the antibacterial activity of the EBP-produced LMCW results 
from the LMCW interaction with the cell walls of microorganisms. This mechanism was 
considered in detail in [24]. 
 The EBP-stimulated degradation mechanisms occurring both in polysaccharides and 
high molecular weight proteins are similar and occur due to the plasmachemical 
processes, whereas the attendant of fast electrons and X-ray irradiations are minor 
factors only.The active oxygen species produced in plasmachemical reactions and the 
products of water plasmolisys are responsible for the LMWC and chitooligosaccharides 
formation. Parameters of the treatment process can be adjusted by the control system of 
the EBPR and the results of the modification are predictable. 
12. Future developments 
1. Our experiments have demonstrated that the EBP can be used for the effective and 
controllable modification of some natural biopolymers. Using various plasma-
generating gases the functional groups containing sulfur, nitrogen, phosphorus can be 
introduced into the biopolymer structure to obtain substances with unique 
pharmacological and biological activities (anticoagulant, hemostatic, antibacterial, etc.);  
2. On the basis of present study the novel strategies of plasma-stimulated synthesis and 
plasma-assisted bioactive coating deposition can be developed. Two different ways of 
the plasma-assisted formation of bioactive coatings by means of the deposition of 
organic and inorganic vapors activated by the electron beam are possible: 1) on a 
preliminary prepared plane substrate; 2) on a surface of powder particles levitating in 
the plasma trap. The following materials can be synthesized:   
 supramolecular complexes “protein-drug agent” or “polysaccharide- drug agent” 
for the addressed drug delivery;  
 medical hybrid materials and coatings with high bio- and hemo-compatibility 
and/or combined pharmacological action (e.g. haemostatics with antimicrobial or 
regenerative properties); 
3. The technique is potentionally interesting for: 
 increasing the wettability of the original organic and inorganic materials to obtain 
effective sorbents, membranes for hemodialysis, and microbiological substrates; 
 improving membranes selectivity and stability and production more sensitive 
biosensors. 
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